Apolipoprotein C-III, hypertriglyceridemia and triglyceride-rich lipoproteins in uremia

Mineral and Electrolyte Metabolism

Volumn 25, Issue 4-6, 1999, Pages 258-262

  Moberly, James B ^a   Attman, Per Ola ^c   Samuelsson, Ola ^c   Johansson, Ann Cathrine ^c   Knight Gibson, Carolyn ^b   Alaupovic, Petar ^b  

^a BAXTER HEALTHCARE CORPORATION   (United States)

^b OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^c MPGR A2E ^*

Author keywords

ApoC III; Chronic renal failure; Dyslipidemia; Hemodialysis; Peritoneal dialysis; Plasma triglycerides

Indexed keywords

APOLIPOPROTEIN C3; TRIACYLGLYCEROL;

ADULT; AGED; CONFERENCE PAPER; CONTROLLED STUDY; DYSLIPIDEMIA; HEMODIALYSIS PATIENT; HUMAN; LIPOLYSIS; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; PERITONEAL DIALYSIS; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; UREMIA;

EID: 0033398622     PISSN: 03780392     EISSN: None     Source Type: Journal    
DOI: 10.1159/000057457     Document Type: Conference Paper

References (22)

1. Havel RJ, Kane JP: Introduction: Structure and metabolism of plasma lipoproteins: in Scriver CR, Beaudet AL, Sly WS, Valle D (eds): The Metabolic and Molecular Basis of Inherited Disease. New York, McGraw Hill Inc, 1995. pp 1841-1851.
2. Dammerman M, Sankuijl LA, Halaas J, Chung W, Breslow J: An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms. Proc Natl Acad Sci USA 1993; 90:4562-4566.
3. Pullinger CR, Mallow MJ, Shahidi AK, Ghassemzadeh M, Duchateau P, Villagomez J, Allaart J, Kane JP: A novel apolipoprotein C-III variant apoC-III(G1n38-Lys), associated with moderate hypertriglyceridemia in a large kindred of Mexican origin. J Lipid Res 1997;38: 1833-1840.
4. Windler E, Havel RJ: Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride rich lipoproteins and their remnants by the perfused rat liver. J Lipid Res 1985;26:556-565.
5. Wojciechowski AP, Farrall M, Cullen P, Wilson TME, Bayliss JD, Farren B, Griffin BA, Caslake MJ, Packard CJ, Shepherd J, Thakker R, Scott J: Familial conbined hyperlipidaemia linked to the apolipoprotein AI-CIII-AIV gene cluster on chromosome 11q23-q24. Nature 1991;349:161-164.
6. Ito Y, Azrolan N, O'connell A, Walsh A, B reslow J: Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science 1990;249:790-793.
7. Maeda N, Li H, Lee D, Oliver P, Quarfordt SH, Osada J: Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. J Biol Chem 1994;269: 23610-23616.
8. Attman PO, Alaupovic P: Lipid abnormalities in chronic renal insufficiency. Kidney Int 1991; 39(suppl31):S16-S23.
9. Attman PO, Alaupovic P, Tavella M, Knight-Gibson C: Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure. Ncphrol Dial Transplant 1996;11:63-69.
10. Attman PO, Alaupovic P: Lipid and apolipoprotein profiles of uremic dyslipoproteinemia-relation to renal function and dialysis. Nephron 1991;57:401-410.
11. Samuelsson O, Attman PO, Knight-Gibson C, Kron B, Larsson R, Mulec H, Weiss L, Alaupovic P: Lipoprotein abnormalities without hyperlipidemia in moderate renal insufficiency. Nephrol Dial Transplant 1994;9:1580-1585.
12. Alaupovic P, Mack WJ, Knight-Gibson C, Hodis HN: The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Arterioscler Thromb 1997;17:715-722.
13. Samuelsson O, Attman PO, Knight-Gibson C, Larsson R, Mulec H, Weiss L, Alaupovic P: Complex apolipoprotein B-containing lipoprotein particles are associated with a higher rate of progression of human chronic renal insufficiency. J Am Soc Nephrol 1998;9:1482-1488.
14. Curry MD, McConathy WJ, Fesmire JD, Alaupovic P: Quantitative determination of human apolipoprotein C-III by electroimmunoassay. Biochem Biophys Acta 1980;617:505-513.
15. Jackson RL, Tajima S, Yamamura T, Yokoyama S, Yamamoto A: Comparison of apolipoprotein C-II-deficient triacylglycerol-rich lipoproteins and trioleoylglycerol/phosphotidylcholine-stabilized particles as substrates for lipoprotein lipase. Biochem Biophys Acta 1986;875:211-219.
16. Aalto-Setälä K, Fisher EA, Chen X, Chajek-Shaul T, Hayek T, Zechner R, Walsh A, Ramakrishnan R, Ginsberg HN, Breslow JL: Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional calabolic rate associated with increased apo CIII and reduced apo E on the particles. J Clin Invest 1992;90:1889-1900.
17. Ebara T, Ramakrishnan R, Steiner G, Shachter NS: Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein C-III-Induced hypertriglyceridemia is not mediated by effects on apolipoprotein Eur J Clin Invest 1997;99:2672-2681.
18. Staels B, Vu-Dac N, Kosykh VA, Saladin R, Fruchart JC, Dallongeville J, Auwerx J: Fibrates down-regulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J Clin Invest 1995;95:705-712.
19. Chen M, Breslow JL, Li W, Leff T: Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: Correlation with changes in plasma triglyceride levels. J Lipid Res 1994;35: 1918-1924.
20. Gruber PJ, Torres-Rosado A, Wolak ML, Leff T: Apo CIII gene transcription is regulated by a cytokine inducible NF-kB element. Nucleic Acids Res 1994;22:2417-2422.
21. Sniderman A, Cianflone K, Kwiterovich PO, Hutchinson T, Barre P, Prichard S: Hyperapobetalipoproteinemia: The major dyslipoproteinemia in patients with chronic renal failure treated with chronic ambulatory peritoneal dialysis. Atherosclerosis 1987;65:257-264.
22. Llopart R, Doñate T, Oliva J, Rodá M, Rousaud F, Gonzalez-Sastre F, Pedreño J, Ordoñez-Llanos J: Triglyceride-rich lipoprotein abnormalities in CAPD-treated patients. Nephrol Dial Transplant 1995;10:537-540.